FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985992145> ?p ?o ?g. }

• W1985992145 endingPage "1416" @default.
• W1985992145 startingPage "1408" @default.
• W1985992145 abstract "Salla disease and infantile sialic acid storage disorder are autosomal recessive neurodegenerative diseases characterized by loss of a lysosomal sialic acid transport activity and the resultant accumulation of free sialic acid in lysosomes. Genetic analysis of these diseases has identified several unique mutations in a single gene encoding a protein designated sialin (Verheijen, F. W., Verbeek, E., Aula, N., Beerens, C. E., Havelaar, A. C., Joosse, M., Peltonen, L., Aula, P., Galjaard, H., van der Spek, P. J., and Mancini, G. M. (1999) Nat. Genet. 23, 462–465; Aula, N., Salomaki, P., Timonen, R., Verheijen, F., Mancini, G., Mansson, J. E., Aula, P., and Peltonen, L. (2000) Am. J. Hum. Genet. 67, 832–840). From the biochemical phenotype of the diseases and the predicted polytopic structure of the protein, it has been suggested that sialin functions as a lysosomal sialic acid transporter. Here we directly demonstrate that this activity is mediated by sialin and that the recombinant protein has functional characteristics similar to the native lysosomal sialic acid transport system. Furthermore, we describe the effect of disease-causing mutations on the protein. We find that the majority of the mutations are associated with a complete loss of activity, while the mutations associated with the milder forms of the disease lead to reduced, but residual, function. Thus, there is a direct correlation between sialin function and the disease state. In addition, we find with one mutation that the protein is retained in the endoplasmic reticulum, indicating that altered trafficking of sialin is also associated with disease. This analysis of the molecular mechanism of sialic acid storage disorders is a further step in identifying therapeutic approaches to these diseases. Salla disease and infantile sialic acid storage disorder are autosomal recessive neurodegenerative diseases characterized by loss of a lysosomal sialic acid transport activity and the resultant accumulation of free sialic acid in lysosomes. Genetic analysis of these diseases has identified several unique mutations in a single gene encoding a protein designated sialin (Verheijen, F. W., Verbeek, E., Aula, N., Beerens, C. E., Havelaar, A. C., Joosse, M., Peltonen, L., Aula, P., Galjaard, H., van der Spek, P. J., and Mancini, G. M. (1999) Nat. Genet. 23, 462–465; Aula, N., Salomaki, P., Timonen, R., Verheijen, F., Mancini, G., Mansson, J. E., Aula, P., and Peltonen, L. (2000) Am. J. Hum. Genet. 67, 832–840). From the biochemical phenotype of the diseases and the predicted polytopic structure of the protein, it has been suggested that sialin functions as a lysosomal sialic acid transporter. Here we directly demonstrate that this activity is mediated by sialin and that the recombinant protein has functional characteristics similar to the native lysosomal sialic acid transport system. Furthermore, we describe the effect of disease-causing mutations on the protein. We find that the majority of the mutations are associated with a complete loss of activity, while the mutations associated with the milder forms of the disease lead to reduced, but residual, function. Thus, there is a direct correlation between sialin function and the disease state. In addition, we find with one mutation that the protein is retained in the endoplasmic reticulum, indicating that altered trafficking of sialin is also associated with disease. This analysis of the molecular mechanism of sialic acid storage disorders is a further step in identifying therapeutic approaches to these diseases. Lysosomes are intracellular acidic organelles filled with hydrolytic enzymes. They are primarily responsible for the compartmentalized degradation of macromolecules as part of an intrinsic turnover process and as a mechanism for processing endocytosed nutrients. The importance of these organelles in normal cellular functions is apparent from the phenotype of a group of degenerative diseases designated as lysosomal storage disorders (3Schiffmann R. Brady R.O. Drugs. 2002; 62: 733-742Crossref PubMed Scopus (91) Google Scholar, 4Moser H.W. Curr. Opin. Neurol. Neurosurg. 1992; 5: 355-358PubMed Google Scholar). The hallmark of these disorders is the accumulation of material within enlarged lysosomes. The typical clinical phenotype is one of a progressive multiorgan involvement with a predominance of neurological dysfunction and often early death. For many of these diseases genetic studies have identified causative mutations, most of which occur in genes encoding enzymes involved in the hydrolysis of macromolecules. The major products of the enzymatic processes in lysosomes are small organic molecules. While the membrane-bound nature of the organelle allows for hydrolytic enzymes to be isolated from the cytosol, it also requires mechanisms for the release of these end products. Biochemical studies have identified several lysosomal transport systems that facilitate the movement of amino acids, nucleotides, lipids, vitamins, and sugars across the lysosomal membrane (5Pisoni R.L. Thoene J.G. Biochim. Biophys. Acta. 1991; 1071: 351-373Crossref PubMed Scopus (94) Google Scholar, 6Mancini G.M. Havelaar A.C. Verheijen F.W. J. Inherit. Metab Dis. 2000; 23: 278-292Crossref PubMed Scopus (45) Google Scholar). However, the molecular identification of the lysosomal transport systems has been difficult. Their intracellular localization and the presence of lysosomes or an equivalent organelle in all eukaryotic cells have hampered the use of expression cloning. Genetic studies of lysosomal storage disorders have offered some insight into the molecular mechanisms of the transport processes. For example, the gene mutated in cystinosis has been shown to encode a lysosomal cystine transporter (7Town M. Jean G. Cherqui S. Attard M. Forestier L. Whitmore S.A. Callen D.F. Gribouval O. Broyer M. van't Bates G.P. Hoff W. Antignac C. Nat. Genet. 1998; 18: 319-324Crossref PubMed Scopus (466) Google Scholar), while a fatty acid transporter (NPC1) localized to lysosomes and endosomes has been shown to be the product of a gene mutated in Niemann-Pick disease Type C (8Davies J.P. Chen F.W. Ioannou Y.A. Science. 2000; 290: 2295-2298Crossref PubMed Scopus (255) Google Scholar, 9Loftus S.K. Morris J.A. Carstea E.D. Gu J.Z. Cummings C. Brown A. Ellison J. Ohno K. Rosenfeld M.A. Tagle D.A. Pentchev P.G. Pavan W.J. Science. 1997; 277: 232-235Crossref PubMed Scopus (698) Google Scholar). Recent evidence also indicates that CLN3, the protein mutated in one form of Batten Disease, mediates a lysosomal arginine-H+ antiport activity (10Kim Y. Ramirez-Montealegre D. Pearce D.A. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 15458-15462Crossref PubMed Scopus (90) Google Scholar). Salla disease and infantile sialic acid storage disorder (ISSD) 1The abbreviations used are: ISSD, infantile sialic acid storage disorder; EST, expressed sequence tag; HA, hemagglutinin; AP, adaptor protein; MES, 4-morpholineethanesulfonic acid; DIDS, 4,4′-diisothiocyanostilbene-2,2′-disulfonic acid; ER, endoplasmic reticulum; PDI, protein disulfide-isomerase.1The abbreviations used are: ISSD, infantile sialic acid storage disorder; EST, expressed sequence tag; HA, hemagglutinin; AP, adaptor protein; MES, 4-morpholineethanesulfonic acid; DIDS, 4,4′-diisothiocyanostilbene-2,2′-disulfonic acid; ER, endoplasmic reticulum; PDI, protein disulfide-isomerase. are autosomal recessive lysosomal storage disorders with common features but differing degrees of severity (1Verheijen F.W. Verbeek E. Aula N. Beerens C.E. Havelaar A.C. Joosse M. Peltonen L. Aula P. van der Galjaard H. Spek P.J. Mancini G.M. Nat. Genet. 1999; 23: 462-465Crossref PubMed Scopus (218) Google Scholar, 2Aula N. Salomaki P. Timonen R. Verheijen F. Mancini G. Mansson J.E. Aula P. Peltonen L. Am. J. Hum. Genet. 2000; 67: 832-840Abstract Full Text Full Text PDF PubMed Scopus (90) Google Scholar). Salla Disease is characterized by developmental delay with marked cognitive and motor impairment noticeable at 6–12 months of age. However, many affected individuals reach adulthood (11Varho T.T. Alajoki L.E. Posti K.M. Korhonen T.T. Renlund M.G. Nyman S.R. Sillanpaa M.L. Aula P.P. Pediatr. Neurol. 2002; 26: 267-273Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar). ISSD has a more severe phenotype with intrauterine hydrops, neonatal ascites, dysmorphic features, and death by 2 years of age. The cellular pathology for both diseases consists of enlarged lysosomes filled with high concentrations of free sialic acid, an amino sugar related to neuraminic acid (12Aula P. Autio S. Raivio K.O. Rapola J. Thoden C.J. Koskela S.L. Yamashina I. Arch. Neurol. 1979; 36: 88-94Crossref PubMed Scopus (107) Google Scholar, 13Virtanen I. Ekblom P. Laurila P. Nordling S. Raivio K.O. Aula P. Pediatr. Res. 1980; 14: 1199-1203Crossref PubMed Scopus (19) Google Scholar, 14Renlund M. Aula P. Raivio K.O. Autio S. Sainio K. Rapola J. Koskela S.L. Neurology. 1983; 33: 57-66Crossref PubMed Google Scholar). The free sialic acid is derived from the oligosaccharide chains of sialylated glycoproteins and glycolipids that have been degraded in the lysosme. Previous studies have demonstrated that individuals with Salla disease and ISSD accumulate free sialic acid in their lysosomes due to a defect in a proton-coupled sialic acid transport activity (14Renlund M. Aula P. Raivio K.O. Autio S. Sainio K. Rapola J. Koskela S.L. Neurology. 1983; 33: 57-66Crossref PubMed Google Scholar, 15Renlund M. Tietze F. Gahl W.A. Science. 1986; 232: 759-762Crossref PubMed Scopus (101) Google Scholar, 16Tietze F. Seppala R. Renlund M. Hopwood J.J. Harper G.S. Thomas G.H. Gahl W.A. J. Biol. Chem. 1989; 264: 15316-15322Abstract Full Text PDF PubMed Google Scholar). Despite clear differences in the severity of the clinical phenotypes, both forms of the disease are associated with no detectable lysosomal sialic acid transport. Genetic studies of individuals with Salla Disease led to the determination that a gene encoding a protein designated sialin contains the causative mutations (1Verheijen F.W. Verbeek E. Aula N. Beerens C.E. Havelaar A.C. Joosse M. Peltonen L. Aula P. van der Galjaard H. Spek P.J. Mancini G.M. Nat. Genet. 1999; 23: 462-465Crossref PubMed Scopus (218) Google Scholar). Sialin is a member of the anion/cation symporter (ACS) family of proteins and has a high degree of similarity to the vesicular glutamate transporters (VGUT1–3) (17Reimer R.J. Edwards R.H. Pfluegers Arch. 2004; 447: 629-635Crossref PubMed Scopus (149) Google Scholar). To date 16 mutations in sialin have been associated with the disease phenotype (2Aula N. Salomaki P. Timonen R. Verheijen F. Mancini G. Mansson J.E. Aula P. Peltonen L. Am. J. Hum. Genet. 2000; 67: 832-840Abstract Full Text Full Text PDF PubMed Scopus (90) Google Scholar). The most common mutation (R39C) is found in Salla disease. The more severe ISSD is associated with four other missense mutations (K136E, H183R, P334R, G371V), a short deletion (Δ268–272), and 10 mutations that lead to early truncations or large deletions. To better understand the mechanisms by which mutations may lead to disease, we sought to characterize the function of sialin. By altering a potential lysosomal targeting domain we are able to express the protein on the cell surface allowing for the use of whole cell uptake assays to measure transport activity. Using this approach we directly demonstrate that sialin is a sialic acid transporter with characteristics similar to those of the native lysosomal transport system. Through characterizing the effect of disease-associated mutations on transport activity we show a direct correlation between the degree of transport activity lost and the severity of the clinical phenotype. In addition, we demonstrate that one mutation leads to retention of the protein in the endoplasmic reticulum, suggesting that altered trafficking of sialin can also contribute to the pathophysiology of these disorders. Isolation of Rat Sialin cDNA and Mutagenesis—The predicted human sialin peptide sequence was used to identify expressed sequence tags (ESTs) in the rat sequence data base (NCBI). Oligonucleotides corresponding to the 5′ and 3′ ends of the coding sequence were generated and high fidelity PCR (Turbo Pfu, Stratagene) was used to amplify the sequence from PC12 cell cDNA. The cDNA was subcloned into the expression vector pcDNA3 (Invitrogen). To introduce disease-associated mutations and restriction sites for epitope tagging, site-directed mutagenesis was carried out with the QuikChange kit (Stratagene) following the directions of the manufacturer. The DNA was submitted to a commercial sequence facility for ABI automated sequencing to confirm generation of the desired mutation. To facilitate the generation of a subset of constructs an NheI site was introduced into the amino-terminal portion of the protein resulting in a conservative mutation (N41G), which did not alter the localization or function of the protein. Cell Culture and Heterologous Expression—HeLa cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) with 10% Cosmic-calf serum (Hyclone). All cultures were kept at 37 °C in 5% CO2, and all media contained penicillin and streptomycin. To transiently express cDNAs in HeLa cells, Effectene (Qiagen) was used according to the instructions of the manufacturer. For cotransfection, equal amounts of DNA were used with the total amount corresponding to that recommended by the manufacturer. Immunofluorescence of Cultured Cells—HeLa cells were plated at 80,000 per well in 24-well plates. Approximately 20 h later the cells were transfected as described above and the following day split ∼1:3 onto glass coverslips pretreated with poly-d-lysine (Sigma). Immunofluorescence staining was carried out as described previously (18Kent H.M. McMahon H.T. Evans P.R. Benmerah A. Owen D.J. Structure (Camb.). 2002; 10: 1139-1148Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar) and coverslips mounted on glass slides using Mowiol (Calbiochem). The rabbit anti-HA antibody (Abcam) was used at 1:2,000 and the mouse anti-PDI antibody (Stressgen) was used at 1:50. Secondary antibodies labeled with Alexa 488 or Alexa 568 (Molecular Probes) were diluted at 1:1,000. Zeiss Axiovert 100M inverted microscope configured for confocal microscopy (LSM 5 PASCAL, Zeiss) was used for imaging. Transport Assay—HeLa cells were plated on 24-well plates at a density of 70,000 per well and the following day transfected as described above. After 24–36 h, transport assays with radiolabeled N-acetylneuraminic acid (0.05 μCi/well (∼3.6 μm final concentration)) (American Radiolabeled Chemicals) were carried out as described previously (19Wreden C.C. Johnson J. Tran C. Seal R.P. Copenhagen D.R. Reimer R.J. Edwards R.H. J. Neurosci. 2003; 23: 1265-1275Crossref PubMed Google Scholar). For controls LYAAT1, a lysosomal transporter previously characterized with whole cell uptake assays (19Wreden C.C. Johnson J. Tran C. Seal R.P. Copenhagen D.R. Reimer R.J. Edwards R.H. J. Neurosci. 2003; 23: 1265-1275Crossref PubMed Google Scholar), was used and the background was subtracted for saturation, inhibition, and pH dependence studies. Statistical analyses were performed using the Prism program (GraphPad Software). For the time course each point is the mean of two separate samples. For all other experiments results are from four experiments with error bars indicating the standard error of the mean. Labeling of Cell Surface Proteins—Cells in the wells of a 24-well plate were rinsed twice with CMF-PBS and then 300 μl of CMF-PBS with 5 mm EDTA was added to each well. Cells were triturated and samples from 3 wells were combined. After centrifugation at 800 × g the cells were rinsed with 500 μl of ice-cold borate buffered saline (50 mm borate, 150 mm NaCl, pH 8.2) and then incubated in 125 μl of 2 mm sulfo-NHS-LC-Biotin (Pierce) in borate buffered saline for 30 min on ice. 500 μl of CMF-PBS with 10 mm glycine was then added to quench the labeling reaction. After pelleting the cells, biotinylated proteins were isolated on NeutrAvadin beads (Pierce) as described previously (20Seal R.P. Leighton B.H. Amara S.G. Neuron. 2000; 25: 695-706Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar). Western Analysis—Samples were separated on an SDS-polyacrylamide gel, transferred to polyvinylidene difluoride membranes (Pall), and immunoblotted as described previously (21Chaudhry F.A. Reimer R.J. Bellocchio E.E. Danbolt N.C. Osen K.K. Edwards R.H. Storm-Mathisen J. J. Neurosci. 1998; 18: 9733-9750Crossref PubMed Google Scholar). Detection of hybridization was done with enhanced chemiluminescence (Amersham Biosciences) and exposure of the blot to autoradiography film (Cole Parmer Blue-Sensitive) for 15 s to 5 min. The rabbit anti-HA antibody (Chemicon) was used at 1:1,000, and the horseradish peroxidase-linked anti-rabbit antibody (Pierce) was used at 1:10,000. Determination of Relative Specific Transport Activity—To determine relative specific activity, transport activity and quantitative analysis of cell surface expression were carried out in parallel experiments for the wild-type, R39C, and K136E mutants with the dileucine motifs disrupted. Transport was measured at 3 min as described above. For quantification of cell surface protein expression Western blots were scanned and converted to a TIFF file for analysis. Regions of interest were identified and quantified in density units using NIH Image. The corresponding region in a lane with a sample from cells transfected the untagged LYAAT1 protein was measured as background and subtracted from all values. Relative specific activity for each mutant was calculated from the following equation: [uptake by mutant (pmols/3 min)/uptake by wild type (pmols/3 min)]/[mutant expression level (density units)/wild-type expression level (density units)]. Mutations Associated with Disease Occur in Conserved Residues—To facilitate the characterization of the physiological role of sialin we identified a rat orthologue of the human protein. A BLAST search of available rat ESTs led to the identification of separate ESTs corresponding to the 5′ and 3′ ends of the rat sialin cDNA. Oligonucleotide primers were designed to generate a sequence corresponding to the open reading frame of the cDNA. Amplification of the sequence generated a cDNA that predicts a 495-amino acid peptide with 12 transmembrane domains and 86% identity and 90% similarity to the human protein. A similar degree of homology is also noted in comparisons of the rat or human sequences to the identified murine or ovine sequences (Fig. 1). Sequence comparison of the mammalian proteins indicates that the disease-causing point mutations occur throughout the protein with no obvious clustering. The predicted topology suggests that the mutations occur in residues within (H183R, P334R, and G371V) or abutting (R39C, K136E) transmembrane domains. In contrast, the amino acids excised in the short deletion are in the middle of a well defined extramembraneous region. The residues associated with the mutations are highly conserved among the mammalian proteins; the only variation is a single conservative substitution in the deleted segment of one species. The absence of structure-function analysis of sialin or related proteins precludes predictions about the influence of the mutations based on their location in the protein. Disruption of Putative Adaptor Protein-binding Domain Leads to Plasma Membrane Expression of Sialin—Measuring transport activity of recombinant sialin is complicated by the fact that the protein is likely expressed in all cells of higher eukaryotic organisms. To circumvent the problem of endogenous lysosomal sialic acid transport activity we sought to generate a form of sialin that traffics to the cell surface, thus allowing for whole cell uptake assays to measure activity of the recombinant protein. While a plasma membrane sialic acid transport activity has been described (22Hirschberg C.B. Goodman S.R. Green C. Biochemistry. 1976; 15: 3591-3599Crossref PubMed Scopus (32) Google Scholar), we found no measurable uptake in intact HeLa cells, suggesting that this approach would be feasible. In analyzing sialin sequences from different species we noted a short sequence (DXXPLL) in the cytosolic amino terminus that is conserved from Xenopus laevis to humans (Fig. 2A). A dileucine with an acidic amino acid 4 residues upstream is a consensus motif for adaptor protein (AP) binding (23Bonifacino J.S. Traub L.M. Annu. Rev. Biochem. 2003; 72: 395-447Crossref PubMed Scopus (1651) Google Scholar). Since interactions with AP1 or AP3 are required for proper targeting of some lysosomal membrane proteins (23Bonifacino J.S. Traub L.M. Annu. Rev. Biochem. 2003; 72: 395-447Crossref PubMed Scopus (1651) Google Scholar), we sought to determine whether this domain in sialin is involved in trafficking. We first replaced the amino-terminal cytosolic domain of sialin, containing the motif, with the corresponding region of NaPi-1, a structurally related protein that resides on the plasma membrane (24Busch A.E. Schuster A. Waldegger S. Wagner C.A. Zempel G. Broer S. Biber J. Murer H. Lang F. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 5347-5351Crossref PubMed Scopus (133) Google Scholar). When heterologously expressed in HeLa cells, the HA-tagged chimeric protein no longer displays a pattern of large puncta typical of lysosomal antigens but stains finer structures within the cell. It also appears to be present on the plasma membrane (Fig. 2B). To further refine the sequence necessary for lysosomal targeting, in separate constructs we mutated the leucines and altered the spacing between the leucines and the acidic residue. These changes have been shown to disrupt the interaction of the lysosomal protein LIMP2 with AP3 and to alter targeting of the protein (25Sandoval I.V. Martinez-Arca S. Valdueza J. Palacios S. Holman G.D. J. Biol. Chem. 2000; 275: 39874-39885Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar). Replacing both leucines with alanines (L22A,L23A) or inserting two additional amino acids (alanines) between the acidic residue and the dileucine of sialin (20AAins21) resulted in an expression pattern similar to the NaPi-1-sialin chimera, indicating that this specific motif within the amino terminus facilitates lysosomal targeting of sialin (Fig. 2B). Sialin Is a pH-dependent Sialic Acid Transporter—Disruption of the targeting sequence enables measurements of activity at the plasma membrane through whole cell uptake assays. The orientation of the protein, with the lumenal side facing out, is such that whole cell uptake corresponds to the transport of sialic acid out of the lysosome. Transporters are often reversible, but asymmetries in relative affinity can exist at the two sides of the transporter. Even though the physiologically relevant activity for the lysosomal sialic acid transport system is to mediate the outward movement of sialic acid, the most comprehensive studies on the native transport system have relied on the reversibility of the transport system and measured uptake into intact lysosomes (26Mancini G.M. de Jonge H.R. Galjaard H. Verheijen F.W. J. Biol. Chem. 1989; 264: 15247-15254Abstract Full Text PDF PubMed Google Scholar, 27Mancini G.M. Beerens C.E. Aula P.P. Verheijen F.W. J. Clin. Invest. 1991; 87: 1329-1335Crossref PubMed Scopus (63) Google Scholar, 28Havelaar A.C. Beerens C.E. Mancini G.M. Verheijen F.W. FEBS Lett. 1999; 446: 65-68Crossref PubMed Scopus (13) Google Scholar). With sialin mistargeted to the cell surface, however, the activity measured will more directly reflect the physiologically relevant function of the protein. For initial studies, to make the extracellular environment approximate the acidic lysosomal lumen, the cells were incubated in a Krebs-Ringer solution buffered with MES at pH 5.5. A marked time-dependent increase in the uptake of sialic acid is seen in cells expressing plasma membrane targeted sialin compared with cells expressing another lysosomal transporter protein, LYAAT1 (Fig. 3, A and B). The activity is saturable with a Km of ∼0.8 mm, which is similar to, but slightly higher than, the value reported for the uptake of sialic acid into lysosomes (Fig. 3C). Sialic acid uptake is not affected by switching to a Na+- and Cl--free MES-buffered sucrose solution (data not shown), indicating that the activity is not dependent on, or inhibited by, either of these ions. However, uptake is reduced by two known inhibitors of lysosomal sialic acid uptake, glucuronic acid and DIDS (Fig. 3D). A large pH gradient exists across the lysosomal membrane and several lysosomal transport systems, including the sialic acid transport system, are coupled to this gradient. To determine the role of pH in the activity of the recombinant protein, both the pH of the buffer solution and the pH gradient across the plasma membrane were varied. Increasing the buffer pH from 5.5 to 6.5 markedly decreases sialin mediated transport, and essentially no transport is detected when the extracellular solution is buffered at approximately the same pH as the cytoplasm (pH 7.5) (Fig. 3E). In addition, uptake is reduced by ∼80% at pH 5.5 by abolishing the pH gradient with nigericin, an ionophore that mediates H+/K+ exchange (Fig. 3F). On the other hand, transport activity is not affected by specific dissipation of the electrical gradient using the K+ ionophore valinomycin, suggesting that transport is electroneutral. A Subset of Mutations Is Associated with Residual Transport Activity—After confirming that sialin is a sialic acid transporter, we next sought to determine whether mutations associated with disease alter the intrinsic transport activity of the protein. To do this, we disrupted the putative AP-binding domain of proteins containing the disease-associated mutations (R39C, K136E, H183R, P334R, G371V, and Δ268–272(SSLRN)). This leads to plasma membrane expression of all of the proteins with the exception of G371V, as indicated by the pattern of immunofluorescence staining (Fig. 4A) and cell surface biotinylation (data not shown). Measuring total uptake at 5 min (Fig. 4B) demonstrates that the transport activity of the R39C and K136E mutants is reduced. Whereas, essentially no transport activity can be detected for the other mutants (H183R, P334R, G371V, and Δ268–272(SSLRN)). The absence of measurable activity associated with the H183R and P334R mutations and the short deletion despite plasma membrane expression strongly suggests that these mutations abolish transporter activity. However, since G371V is not present at detectable levels on the plasma membrane, with this approach we cannot determine whether the mutation influences the intrinsic transport activity of the protein. Although a partial reduction in transport activity could lead to disease, the absence of a phenotype in heterozygote carriers of the free sialic acid storage disorders, who have approximately half the normal lysosomal sialic acid transport activity (27Mancini G.M. Beerens C.E. Aula P.P. Verheijen F.W. J. Clin. Invest. 1991; 87: 1329-1335Crossref PubMed Scopus (63) Google Scholar), suggests that activity would need to be reduced by more than 50%. Therefore, we wanted to know, more precisely, the effect of the R39C and K136E mutations on activity. To accomplish this, we analyzed sialic acid uptake relative to the amount of biotinylated cell surface protein expresssion. For both mutants, uptake and plasma membrane expression were determined relative to transfected wild-type protein. Normalizing relative uptake to relative biotinylated cell surface expression demonstrates that both the Salla mutation and the K136E mutation retain only about 10% of their intrinsic transport activity (Fig. 4C). The G371V Mutation Leads to Retention of Sialin in the ER—In a previous report in which the localization of sialin was compared with LAMP1, a lysosomal/late endosomal marker, recombinant proteins with the Salla mutation and the short deletion were found to be mislocalized, leading the authors to suggest that improper targeting could contribute to the defect associated with these mutations (29Aula N. Jalanko A. Aula P. Peltonen L. Mol. Genet. Metab. 2002; 77: 99-107Crossref PubMed Scopus (30) Google Scholar). In trying to determine the extent to which other mutations influence trafficking of sialin we found that wild-type sialin only partially localizes with LAMP1 and LAMP2 in HeLa cells (data not shown), suggesting that colocalization studies with these endogenous antigens would be difficult. Therefore, to determine whether mutations affect trafficking we compared wild-type and mutant proteins expressed in the same cell using differential epitope tagging. As expected, simultaneous expression of HA-tagged and Myc-tagged wild-type sialin leads to colocalization of the two epitopes by immunofluoresence staining (Fig. 5A). Analysis of cells cotransfected with Myc-tagged wild-type sialin and HA-tagged R39C mutant demonstrates a predominant staining pattern of complete overlap with only rare cells with partial overlap (Fig. 5A). This colocalization is independent of expression levels or time after transfection (data not shown). Similar colocalization with the wild-type protein is seen with other mutants including K136E, H183R, P334R, and the short deletion (Fig. 5A). A striking differential localization is only seen for G371V. This mutant colocalizes with PDI, an endoplasmic reticulum protein, suggesting retention in this compartment (Fig. 5B). Interestingly the combination of G371V with the disrupted putative AP-binding domain also colocalizes with PDI (data not shown), consistent with sialin interacting with an adaptor protein in a post-ER compartment. Characterization of the biochemical phenotype of Salla d" @default.
• W1985992145 created "2016-06-24" @default.
• W1985992145 creator A5003998052 @default.
• W1985992145 creator A5040315285 @default.
• W1985992145 creator A5053421257 @default.
• W1985992145 date "2005-01-01" @default.
• W1985992145 modified "2023-10-18" @default.
• W1985992145 title "Varied Mechanisms Underlie the Free Sialic Acid Storage Disorders" @default.
• W1985992145 cites W120703973 @default.
• W1985992145 cites W1480251615 @default.
• W1985992145 cites W1481327162 @default.
• W1985992145 cites W1503369988 @default.
• W1985992145 cites W1549118128 @default.
• W1985992145 cites W1583245386 @default.
• W1985992145 cites W1788084167 @default.
• W1985992145 cites W1963869388 @default.
• W1985992145 cites W1964692824 @default.
• W1985992145 cites W1974718423 @default.
• W1985992145 cites W1974924348 @default.
• W1985992145 cites W1979216037 @default.
• W1985992145 cites W1991145708 @default.
• W1985992145 cites W1997278734 @default.
• W1985992145 cites W2005096312 @default.
• W1985992145 cites W2017400416 @default.
• W1985992145 cites W2019827360 @default.
• W1985992145 cites W2022470405 @default.
• W1985992145 cites W2027673213 @default.
• W1985992145 cites W2029870086 @default.
• W1985992145 cites W2042412790 @default.
• W1985992145 cites W2044826456 @default.
• W1985992145 cites W2048796422 @default.
• W1985992145 cites W2053699118 @default.
• W1985992145 cites W2055662031 @default.
• W1985992145 cites W2060584495 @default.
• W1985992145 cites W2063916497 @default.
• W1985992145 cites W2065626733 @default.
• W1985992145 cites W2077053416 @default.
• W1985992145 cites W2080562281 @default.
• W1985992145 cites W2082946926 @default.
• W1985992145 cites W2092661111 @default.
• W1985992145 cites W2094972429 @default.
• W1985992145 cites W2101555584 @default.
• W1985992145 cites W2106359719 @default.
• W1985992145 cites W2117143712 @default.
• W1985992145 cites W2125742253 @default.
• W1985992145 cites W2135739141 @default.
• W1985992145 cites W2143266871 @default.
• W1985992145 cites W2148351021 @default.
• W1985992145 cites W2163373697 @default.
• W1985992145 cites W2168016965 @default.
• W1985992145 cites W2299749495 @default.
• W1985992145 cites W2301161050 @default.
• W1985992145 doi "https://doi.org/10.1074/jbc.m411295200" @default.
• W1985992145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15516337" @default.
• W1985992145 hasPublicationYear "2005" @default.
• W1985992145 type Work @default.
• W1985992145 sameAs 1985992145 @default.
• W1985992145 citedByCount "75" @default.
• W1985992145 countsByYear W19859921452012 @default.
• W1985992145 countsByYear W19859921452013 @default.
• W1985992145 countsByYear W19859921452014 @default.
• W1985992145 countsByYear W19859921452016 @default.
• W1985992145 countsByYear W19859921452017 @default.
• W1985992145 countsByYear W19859921452019 @default.
• W1985992145 countsByYear W19859921452020 @default.
• W1985992145 countsByYear W19859921452021 @default.
• W1985992145 countsByYear W19859921452022 @default.
• W1985992145 countsByYear W19859921452023 @default.
• W1985992145 crossrefType "journal-article" @default.
• W1985992145 hasAuthorship W1985992145A5003998052 @default.
• W1985992145 hasAuthorship W1985992145A5040315285 @default.
• W1985992145 hasAuthorship W1985992145A5053421257 @default.
• W1985992145 hasBestOaLocation W19859921451 @default.
• W1985992145 hasConcept C12554922 @default.
• W1985992145 hasConcept C185592680 @default.
• W1985992145 hasConcept C2780115458 @default.
• W1985992145 hasConcept C55493867 @default.
• W1985992145 hasConcept C86803240 @default.
• W1985992145 hasConceptScore W1985992145C12554922 @default.
• W1985992145 hasConceptScore W1985992145C185592680 @default.
• W1985992145 hasConceptScore W1985992145C2780115458 @default.
• W1985992145 hasConceptScore W1985992145C55493867 @default.
• W1985992145 hasConceptScore W1985992145C86803240 @default.
• W1985992145 hasIssue "2" @default.
• W1985992145 hasLocation W19859921451 @default.
• W1985992145 hasOpenAccess W1985992145 @default.
• W1985992145 hasPrimaryLocation W19859921451 @default.
• W1985992145 hasRelatedWork W1531601525 @default.
• W1985992145 hasRelatedWork W2319480705 @default.
• W1985992145 hasRelatedWork W2384464875 @default.
• W1985992145 hasRelatedWork W2606230654 @default.
• W1985992145 hasRelatedWork W2607424097 @default.
• W1985992145 hasRelatedWork W2748952813 @default.
• W1985992145 hasRelatedWork W2899084033 @default.
• W1985992145 hasRelatedWork W2948807893 @default.
• W1985992145 hasRelatedWork W4387497383 @default.
• W1985992145 hasRelatedWork W2778153218 @default.
• W1985992145 hasVolume "280" @default.

• next